APPLICANT'S

Attorney Docket: 92114.005US1	Serial No.: 10/607,623
Applicant: Haim Danenberg	
William Phases - Bill (577/55)	Charles Aug 3 Years 5 2 3 3

INFORMATION DISCLOSURE CITATION (Substitute Form PTO-1449B) Filing Date: 06/27/03 Group Art Unit: 1614 NON PATENT LITERATURE DOCUMENTS Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue lminiais No. Translation number(s), publisher, city and/or country where published. European Search Report and Written Opinion for related EP application ☐ Y≪ ☐ No i. 06795155.8-2112 dated September 14, 2009. ☐ Abstract 図 N/A ☐ Yes ☐ No Luckman, et al., "Nitrogen-Containing Bisphosphonates Inhibit the Mevalonate 2 ☐ Abstract Ø N/A Pathway and Prevent Post-Translational Prenylation of GTP-Binding Proteins, Including Rus," J. Bone Min. Res., 13:581-589 (1998). OY#ONO 3. Non-Final Office Action dated November 26, 2007 in prosecution of related ☐ Abstract 🔯 N/A application 10/871,488. III Vas III No Applicants' response to November 26, 2007 Non-Final Office Action filed February 4, ☐ Abstract Ø N/A 25, 2008 in prosecution of related application 10/871,488. Non-Final Office Action dated May 21, 2008 in prosecution of related application 5. ☐ Abstract ☐ N/A 10/871,488. ☐ Yes ☐ No Examiner Interview Summary dated July 3, 2008 in prosecution of related 6. application 10/871,488. ☐ Yes ☐ No 7. Presentation by Inventor Yoram Richter from Examiner Interview submitted August ☐ Abstract Ø N/A 21, 2008 in prosecution of related application 10/871,488. ☐ Yes ☐ No Rule 132 Declaration by Inventor Yoram Richter submitted August 21, 2008 in 8. ☐ Abstract 図 N/A prosecution of related application 10/871,488. ☐ Yes ☐ No. 9. Applicants' response to May 21, 2008 Non-Final Office Action filed August 21, Abstract N/A 2008 in prosecution of related application 10/871,488. TYes D No Non-Pinal Office Action dated September 25, 2008 in prosecution of related 10. C Absonics S N/A application 10/871,488. ☐ Yes ☐ No. 11. Applicants' response to September 25, 2008 Non-Final Office Action filed January Abstract XI N/A 26, 2009 in prosecution of related application 10/871,488. ☐ Yes ☐ No 12. Applicants' supplemental response to September 25, 2008 Non-Final Office Action filed January 26, 2009 in prosecution of related application 10/871,488. 🔲 Abstract 🖾 N/A ☐ Yes ☐ No Boras, et al., "Diabetes and Coronary Heart Disease," Endocrinology and 13. ☐ Abstract 🔯 N/A Metabolic Diseases, 31-4:199-208 (2002), ☐ Yes ☐ No 14 "Unnerving Truth About Disbetic Neuropathy," Diabetes Facts, Diabetes Research, C Abstract X N/A http://www.allaboutdiabetes.net/unnerving-truth-about-diabetic-neuropathy... Non-Final Office Action dated April 16, 2009 in prosecution of related application 15. 10/871,488. ☐ Abstract 🔯 N/A ☐ Yes ☐ No. 16. Applicants' response to April 16, 2009 Non-Final Office Action filed July 13, 2009 C Abstract 2 N/A in prosecution of related application 10/871,488. □ Yes □ No 17. Final Office Action dated October 29, 2009 in prosecution of related application ☐ Abstract XI N/A 10/871,488.

\			
Examiner	Date		
Signature	Considered		
EXAMPLES:	Initial if reference considered, whether or not criation is in comformance with MPEP \$609.		
Draw line through situation if not in conformance and not considered.			
	Include copy of this form with pext communication to applicant.		

APPLICANT'S

Attorney Docket:	92114.005US1	*******	Serial No.:	10/607,623
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,,,,,,,	******************	***********************

			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			
INFORMATION DISCLOSURE CITATION (Substitute Form PTO-1449B)		Applicant: Haim Danenberg				
		Filing Date: 06/27/03 Group		An Unit: 1614		
	***************************************	NON PATENT LITE	RATURE DOCUMENTS			
Examiner Initials	Cite No.	fucinds name of the author (in CAPITAL LETTERS), tide of the article (when appropriate), title of the item (bank, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			Translation	
	18.	Restriction Requirement dated July 29, 2008 in prosecution of related application			☐ Yes ☐ No ☐ Abstract 図 N/A	
	19.	4 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -			□ Yes □ No □ Abstract ❷ N/A	
	20.				☐ Yes ☐ No ☐ Abstract ❷ N/A	
	21.	Applicants' response to October 29, 200 25, 2009 in prosecution of related applications				
	22.				☐ Yes ☐ №0 ☐ Abstract ☐ N/A	
	23.	Applicants' response to June 11, 2009 b 2009 in prosecution of related application	O Yes O No O Abstract 🖾 N/A			
	24.	Applicants' supplemental response to Jo November 10, 2009 in prosecution of re	O Yes O No O Abeltous O N/A			
	25.	Remington's Pharmaceutical Sciences, A.R. Gennaro, ed., Mack Publishing Co. (18th ed. 1990), pg. 993.			☐ Yes ☐ No ☐ Abstract ☒ N/A	
	26.				O Yes O No O Abstract Ø N/A	
	27.	27. Afergan, et al., "Delivery of serotonin to the brain by monocytes following			□ Yes □ No □ Abstract ⊠ N/A	
	28.				☐ Yes ☐ No ☐ Abstract ☐ N/A	
	29.				O Yes O No O Abstract O N/A	
	30.					
*******************	31,				O Yes O No O Abstract O N/A	
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	32.				☐ Yes ☐ No ☐ Abstract ☐ N/A	
	33.				☐ Yes ☐ No ☐ Abstract ☐ N/A	
	34.				☐ Yes ☐ No ☐ Abstract ☐ N/A	
Examiner Signature		/Donna Jagoe/ (01/19/201	Considered			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered.						

Examiner	/Donna Jagoe/ (01/19/2010)	Date		***************************************	***************************************
Signature	3, ,	Completend			
karangan dan karangan karangan dan Karangan dan Karangan dan karangan dan karangan dan karangan dan karangan d		Constant	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	~~~~	******
EXAMINER			P \$609.		:
Draw line through estation if not in conformance and not considered.					
	Include copy of this form with next communication to applican				
	The state of the s	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	********************	*************	